Biogen Idec (NQ: BIIB )

268.17 USD +2.44 (+0.92%)

Official Closing Price Updated: 5:52 PM EDT, Apr 9, 2021 Add to My Watchlist

Price and Volume

Volume	874,100
Open	265.73
Bid (Size)	264.00 (1)
Ask (Size)	268.17 (7)
Prev. Close	265.73
Today's Range	263.50 - 268.59
52wk Range	223.25 - 363.92
Shares Outstanding	211,007,945
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Biogen Announces Two New Nominees for Election to Board of Directors

April 09, 2021

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

April 08, 2021

Performance

YTD	+10.38%	+10.38%
1 Month	+0.27%	+0.27%
3 Month	+0.24%	+0.24%
6 Month	-8.00%	-8.00%
1 Year	-16.96%	-16.96%

More News

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

April 07, 2021

Top Health Care Stocks Worth Investing In Now? 4 In Focus

March 26, 2021

Noteworthy Friday Option Activity: JNJ, BIIB, BBY

April 09, 2021

Week in Review: Sorrento Acquires ACEA in $488 Million Deal between Two San Diego-China Oncology Biopharmas

April 10, 2021

3 Biotech Stocks With Big Catalysts Around the Corner

April 10, 2021

Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis

April 08, 2021

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

April 09, 2021

Biotech Stocks Could Use A Win — Will The First Quarter Offer That?

April 08, 2021

Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront

April 08, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.